Dianthus Therapeutics (NASDAQ:DNTH) Receives “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Dianthus Therapeutics (NASDAQ:DNTH) in a research report released on Monday morning,Benzinga reports. They currently have a $40.00 price objective on the stock.

A number of other research firms have also issued reports on DNTH. Raymond James increased their target price on Dianthus Therapeutics from $51.00 to $56.00 and gave the company an “outperform” rating in a report on Friday. Wedbush lowered their price target on shares of Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating on the stock in a report on Friday, August 9th. Robert W. Baird assumed coverage on Dianthus Therapeutics in a research report on Friday, July 26th. They set an “outperform” rating and a $58.00 price objective for the company. Oppenheimer upped their target price on Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an “outperform” rating in a research report on Monday. Finally, Baird R W raised Dianthus Therapeutics to a “strong-buy” rating in a research note on Friday, July 26th. Eight analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $46.43.

Dianthus Therapeutics Trading Down 4.5 %

Shares of NASDAQ:DNTH opened at $27.75 on Monday. The company has a 50 day moving average of $27.73 and a 200-day moving average of $26.60. The firm has a market cap of $815.02 million, a P/E ratio of -11.10 and a beta of 1.84. Dianthus Therapeutics has a twelve month low of $6.58 and a twelve month high of $33.77.

Dianthus Therapeutics (NASDAQ:DNTH) last released its earnings results on Thursday, November 7th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). The business had revenue of $2.17 million during the quarter, compared to the consensus estimate of $1.07 million. Dianthus Therapeutics had a negative return on equity of 22.37% and a negative net margin of 1,250.32%. Equities research analysts forecast that Dianthus Therapeutics will post -2.28 EPS for the current year.

Institutional Investors Weigh In On Dianthus Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Quest Partners LLC grew its holdings in shares of Dianthus Therapeutics by 112,400.0% during the third quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock worth $31,000 after purchasing an additional 1,124 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of Dianthus Therapeutics during the second quarter worth $112,000. American Century Companies Inc. raised its stake in Dianthus Therapeutics by 38.6% during the 2nd quarter. American Century Companies Inc. now owns 30,432 shares of the company’s stock worth $788,000 after buying an additional 8,473 shares during the period. The Manufacturers Life Insurance Company bought a new stake in Dianthus Therapeutics in the 2nd quarter valued at $236,000. Finally, WINTON GROUP Ltd acquired a new stake in Dianthus Therapeutics in the 2nd quarter valued at $265,000. 47.53% of the stock is owned by institutional investors and hedge funds.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.